Search

Your search keyword '"A. Niespolo"' showing total 31 results
Start Over Author "A. Niespolo" Topic oncology
31 results on '"A. Niespolo"'

1. Predictive and prognostic value of inflammatory markers in locally advanced rectal cancer (PILLAR) - A multicentric analysis by the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Gastrointestinal Study Group

Author

Giuditta Chiloiro, Angela Romano, Silvia Mariani, Gabriella Macchia, Diana Giannarelli, Luciana Caravatta, Pierfrancesco Franco, Luca Boldrini, Alessandra Arcelli, Almalina Bacigalupo, Liliana Belgioia, Antonella Fontana, Elisa Meldolesi, Giampaolo Montesi, Rita Marina Niespolo, Elisa Palazzari, Cristina Piva, Vincenzo Valentini, and Maria Antonietta Gambacorta

Subjects
Neoadjuvant radiotherapy, Oncology, Inflammatory markers, Radiology, Nuclear Medicine and imaging, Rectal cancer, Prognostic factors, Predictive factors, Settore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA
Published
2023

2. OC-0272 External validation of the Hemo-Eosinophils-Inflammation index as a prognosticator in anal cancer

Author

P. Franco, A. Porreca, M. Di Nicola, G. Mantello, F. Valvo, N. Slim, S. Manfrida, M.A. Gambacorta, F. De Felice, S. Vagge, M. Krengli, E. Palazzari, M.F. Osti, A. Gonelli, G. Catalano, P. Pittoni, M. Lupattelli, M.R. Niespolo, M.E. Rosetto, G. Macchia, O. Durante, F. Munoz, R.M. D'Angelillo, D. Genovesi, and L. Caravatta

Subjects
Oncology, Radiology, Nuclear Medicine and imaging, Hematology
Published
2022

3. A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer: The LaIT-SABR study

Author

L. Nicosia, D. Franceschini, F. Perrone-Congedi, F. Casamassima, M.A. Gerardi, M. Rigo, R. Mazzola, M. Perna, V. Scotti, A. Fodor, A. Iurato, F. Pasqualetti, G. Gadducci, S. Chiesa, R.M. Niespolo, A. Bruni, G. Alicino, L. Frassinelli, P. Borghetti, A. Di Marzo, A. Ravasio, B. De Bari, M. Sepulcri, D. Aiello, G. Mortellaro, C. Sangalli, M. Franceschini, G. Montesi, F.M. Aquilanti, G. Lunardi, R. Valdagni, I. Fazio, Giovanni Scarzello, L. Corti, V. Vavassori, E. Maranzano, S.M. Magrini, S. Arcangeli, Maria Antonietta Gambacorta, V. Valentini, F. Paiar, S. Ramella, N.G. Di Muzio, L. Livi, B.A. Jereczek-Fossa, M.F. Osti, M. Scorsetti, F. Alongi, Nicosia, L, Franceschini, D, Perrone-Congedi, F, Casamassima, F, Gerardi, M, Rigo, M, Mazzola, R, Perna, M, Scotti, V, Fodor, A, Iurato, A, Pasqualetti, F, Gadducci, G, Chiesa, S, Niespolo, R, Bruni, A, Alicino, G, Frassinelli, L, Borghetti, P, Di Marzo, A, Ravasio, A, De Bari, B, Sepulcri, M, Aiello, D, Mortellaro, G, Sangalli, C, Franceschini, M, Montesi, G, Aquilanti, F, Lunardi, G, Valdagni, R, Fazio, I, Scarzello, G, Corti, L, Vavassori, V, Maranzano, E, Magrini, S, Arcangeli, S, Gambacorta, M, Valentini, V, Paiar, F, Ramella, S, Di Muzio, N, Livi, L, Jereczek-Fossa, B, Osti, M, Scorsetti, M, and Alongi, F

Subjects
medicine.medical_specialty, Multivariate analysis, Colorectal cancer, medicine.medical_treatment, SABR volatility model, Oligometastatic disease, Predictive factors, SABR, SBRT, Stereotactic ablative radiotherapy, Retrospective database, Ablative case, medicine, Radiology, Nuclear Medicine and imaging, Lung, business.industry, Hematology, medicine.disease, Radiation therapy, medicine.anatomical_structure, Oncology, Radiology, Predictive factor, business
Abstract

Introduction: Stereotactic ablative radiotherapy (SABR) has been shown to increase survival in oligometastatic disease, but local control of colorectal metastases remains poor. We aimed to identify potential predictive factors of SBRT response through a multicenter large retrospective database and to investigate the progression to the polymetastatic disease (PMD). Material and methods: The study involved 23 centers, and was approved by the Ethical Committee (Prot. Negrar 2019-ZT). 1033 lung metastases were reported. Clinical and biological parameters were evaluated as predictive for freedom from local progression-free survival (FLP). Secondary end-point was the time to the polymetastatic conversion (tPMC). Results: Two-year FLP was 75.4%. Two-year FLP for lesions treated with a BED < 00 Gy, 100–124 Gy, and ≥125 Gy was 76.1%, 70.6%, and 94% (p = 0.000). Two-year FLP for lesion measuring ≤10 mm, 10–20 mm, and >20 mm was 79.7%, 77.1%, and 66.6% (p = 0.027). At the multivariate analysis a BED ≥125 Gy significantly reduced the risk of local progression (HR 0.24, 95%CI 0.11–0.51; p = 0.000). Median tPMC was 26.8 months. Lesions treated with BED ≥125 Gy reported a significantly longer tPMC as compared to lower BED. The median tPMC for patients treated to 1, 2–3 or 4–5 simultaneous oligometastases was 28.5, 25.4, and 9.8 months (p = 0.035). Conclusion: The present is the largest series of lung colorectal metastases treated with SABR. The results support the use of SBRT in lung oligometastatic colorectal cancer patients as it might delay the transition to PMD or offer relatively long disease-free period in selected cases. Predictive factors were identified for treatment personalization.

Published
2022

5. A predictive model of polymetastatic disease from a multicenter large retrospectIve database on colorectal lung metastases treated with stereotactic ablative radiotherapy: The RED LaIT-SABR study

Author

Luca Nicosia, Davide Franceschini, Francesca Perrone-Congedi, Alessandro Molinari, Marianna Alessandra Gerardi, Michele Rigo, Rosario Mazzola, Marco Perna, Vieri Scotti, Andrei Fodor, Aurelia Iurato, Francesco Pasqualetti, Giovanni Gadducci, Silvia Chiesa, Rita Marina Niespolo, Alessio Bruni, Anna Cappelli, Elisa D'Angelo, Paolo Borghetti, Alessandro Di Marzo, Andrea Ravasio, Berardino De Bari, Matteo Sepulcri, Dario Aiello, Gianluca Mortellaro, Claudia Sangalli, Marzia Franceschini, Giampaolo Montesi, Francesco Maria Aquilanti, Gianluigi Lunardi, Riccardo Valdagni, Ivan Fazio, Giovanni Scarzello, Vittorio Vavassori, Ernesto Maranzano, Stefano Maria Magrini, Stefano Arcangeli, Maria Antonietta Gambacorta, Vincenzo Valentini, Fabiola Paiar, Sara Ramella, Nadia Gisella Di Muzio, Mauro Loi, Barbara Alicja Jereczek-Fossa, Franco Casamassima, Mattia Falchetto Osti, Marta Scorsetti, and Filippo Alongi

Subjects
SBRT, Oncology, Oligometastatic disease, Radiology, Nuclear Medicine and imaging, Stereotactic ablative radiotherapy, Colorectal cancer, Predictive factors, SABR, Settore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA
Published
2023

6. PH-0500 Outcome analysis in locally advanced pancreatic cancer: a predictive model (PAULA-1)

Author

Pietro Bonomo, Giuseppe Tarantino, M.E. Rosetto, Liliana Belgioia, N. Simoni, Alessandra Arcelli, F. Bertini, R.M. Niespolo, I. Djan, M. Di Marco, Vieri Scotti, Alessandra Guido, Renzo Mazzarotto, Alessio G. Morganti, Francesco Cellini, Gabriella Macchia, Pietro Gabriele, Salvatore Parisi, Savino Cilla, Michele Fiore, M. Buwenge, Gabriella Mattiucci, and F. Deodato

Subjects
Oncology, medicine.medical_specialty, business.industry, Internal medicine, medicine, Outcome analysis, Radiology, Nuclear Medicine and imaging, Hematology, business, Locally advanced pancreatic cancer
Published
2021

7. Magnetic resonance imaging (MRI) compared with computed tomography (CT) for interobserver agreement of gross tumor volume delineation in pancreatic cancer: a multi-institutional contouring study on behalf of the AIRO group for gastrointestinal cancers

Author

Francesco Dionisi, Francesco Cellini, Giovanna Mantello, F. Navarria, Gabriella Macchia, Luciana Caravatta, R.M. Niespolo, Claudio Vecchi, Gian Carlo Mattiucci, Domenico Genovesi, Aldo Sainato, Vincenzo Fusco, Alessio G. Morganti, Vincenzo Picardi, Roberta Cianci, Vincenzo Valentini, Raffaella Basilico, N. Simoni, Antonino De Paoli, M.E. Rosetto, Consuelo Rosa, Alessandra Guido, Marco Lupattelli, Marta Di Nicola, Andrea Delli Pizzi, Caravatta, Luciana, Cellini, Francesco, Simoni, Nicola, Rosa, Consuelo, Niespolo, Rita Marina, Lupattelli, Marco, Picardi, Vincenzo, Macchia, Gabriella, Sainato, Aldo, Mantello, Giovanna, Dionisi, Francesco, Rosetto, Maria Elena, Fusco, Vincenzo, Navarria, Federico, De Paoli, Antonino, Guido, Alessandra, Vecchi, Claudio, Basilico, Raffaella, Cianci, Roberta, Delli Pizzi, Andrea, Di Nicola, Marta, Mattiucci, Gian Carlo, Valentini, Vincenzo, Morganti, Alessio Giuseppe, and Genovesi, Domenico

Subjects
Male, Aged, Female, Follow-Up Studies, Gastrointestinal Neoplasms, Humans, Magnetic Resonance Imaging, Pancreatic Neoplasms, Prognosis, Radiotherapy Planning, Computer-Assisted, Retrospective Studies, Tomography, X-Ray Computed, Tumor Burden, Observer Variation, Radiotherapy Planning, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, Computer-Assisted, 0302 clinical medicine, MRI GTV pancreatic cancer, Pancreatic tumor, Pancreatic cancer, medicine, Radiology, Nuclear Medicine and imaging, Radiation treatment planning, Tomography, Settore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA, Contouring, medicine.diagnostic_test, business.industry, Soft tissue, Magnetic resonance imaging, Hematology, General Medicine, medicine.disease, X-Ray Computed, Gross tumor volume, Oncology, 030220 oncology & carcinogenesis, business, Nuclear medicine
Abstract

Due to the high soft tissue resolution, magnetic resonance imaging (MRI) could improve the accuracy of pancreatic tumor delineation in radiation treatment planning. A multi-institutional study was proposed to evaluate the impact of MRI on inter-observer agreement in gross tumor volume (GTV) and duodenum delineation for pancreatic cancer compared with computer tomography (CT).Two clinical cases of borderline resectable (Case 1) and unresectable (Case 2) pancreatic cancer were selected. In two sequential steps, diagnostic contrast-enhanced CT scan and MRI sequences were sent to the participating centers. CT-GTVs were contoured while blinded to MRI data sets. DICE index was used to evaluate the spatial overlap accuracy.Thirty-one radiation oncologists from different Institutions submitted the delineated volumes. CT- and MRI-GTV mean volumes were 21.6 ± 9.0 cmDiagnostic MRI resulted in smaller GTV in borderline resectable case with a substantial agreement between observers, and was comparable to CT scan in interobserver variability, in both cases. The greater variability in the unresectable case underlines the critical issues related to the outlining when vascular structures are more involved. The integration of MRI with contrast-enhancement CT, thanks to its high definition of tumor relationship with neighboring vessels, could offer a greater accuracy of target delineation.

Published
2019

8. A Multicenter Large Retrospective Database on the Personalization of Stereotactic Ablative Radiotherapy for Lung Metastases From Colon-Rectal Cancer: The LaIT-SABR Study

Author

Davide Franceschini, Stefano Maria Magrini, Sara Ramella, Vieri Scotti, F. Casamassima, L. Frassinelli, Frank Lohr, Luigi Corti, N. Di Muzio, Claudia Sangalli, I. Fazio, F. Perrone, M. Perna, Stefano Arcangeli, R.M. Niespolo, D. Aiello, Lorenzo Livi, Francesco Pasqualetti, Marta Scorsetti, M. Franceschini, G. Mortellaro, M.F. Osti, B. De Bari, A. Ravasio, Riccardo Valdagni, M. Sepulcri, Silvia Chiesa, Ernesto Maranzano, V. Valentini, A. Di Marzo, F.M. Aquilanti, Fabiola Paiar, Alessio Bruni, Andrei Fodor, Paolo Borghetti, A. Iurato, Filippo Alongi, Michele Rigo, Marianna Alessandra Gerardi, Giampaolo Montesi, Luca Nicosia, L. Vavassori, Rosario Mazzola, Barbara Alicja Jereczek-Fossa, Nicosia, L, Franceschini, D, Perrone, F, Casamassima, F, Gerardi, M, Perna, M, Scotti, V, Fodor, A, Mazzola, R, Rigo, M, Iurato, A, Pasqualetti, F, Chiesa, S, Niespolo, R, Bruni, A, Frassinelli, L, Borghetti, P, Marzo, A, Ravasio, A, De Bari, B, Sepulcri, M, Aiello, D, Mortellaro, G, Sangalli, C, Franceschini, M, Montesi, G, Aquilanti, F, Valdagni, R, Fazio, I, Corti, L, Vavassori, L, Maranzano, E, Magrini, S, Lohr, F, Arcangeli, S, Valentini, V, Paiar, F, Ramella, S, Di Muzio, N, Livi, L, Jereczek-Fossa, B, Osti, M, Scorsetti, M, and Alongi, F

Subjects
Cancer Research, Univariate analysis, medicine.medical_specialty, Radiation, Predictive marker, Colorectal cancer, business.industry, medicine.medical_treatment, medicine.disease_cause, medicine.disease, SABR volatility model, Primary tumor, Radiation therapy, Lesion, colorectal metastase, Oncology, medicine, Radiology, Nuclear Medicine and imaging, KRAS, Radiology, oligometastase, medicine.symptom, business, SABR
Abstract

PURPOSE/OBJECTIVE(S): stereotactic ablative radiotherapy (SABR) has been shown to increase survival rates in oligometastatic disease (OMD), but local control of colorectal metastases still remains poor. We aimed to identify potential predictive factors of SBRT response through a multicenter large retrospective database and to investigate how lung SBRT can impact on the progression to the polymetastatic disease (PMD). MATERIALS/METHODS: the study involved 22 centers, and was approved by the Ethical Committee (Prot. Negrar 2019-ZT). 1023 lung metastases treated with SBRT in 622 patients were reported. The median BED was 105 Gy10. Lesion diameter GTV, PTV volume, dose, fractionations, and site of primary tumor were evaluated as potential predictive marker for SBRT response for the primary end-point local progression-free survival (LPFS). EGFR, KRAS, NRAS, BRAF, and MSI were also evaluated. Secondary end-point was the time to the polymetastatic conversion (ttPMC). RESULTS: the median follow-up was 26 months (range 3-117 months). The median lesion diameter was 13 mm (range 4-58 mm). The 2- and 3-year LPFS were 75.6% and 71%, respectively. At the univariate analysis, BED ≥125Gy10 was associated with improved LPFS (2-year: 94.1% versus 72.6%; P = < 0.0001), single fraction SBRT correlated with better LPFS in the overall population (2-year: 80.6% versus 73.7%; P = 0.03), but no significant difference was observed when considering the population treated with BED > 100 Gy10. Lesion diameter ≤19 mm correlated with improved LPFS (2-year 80% versus 60%; P = < 0.0001). The median ttPMC was 26 months, and the 2-year ttPMC was 54.5%. The median PFS was 11.3 months. After SABR, 36% patients had polymetastatic relapse, 39.5% patients had an oligometastatic relapse, and 24.5% patients had no further relapse. CONCLUSION: the present is the largest series of lung colorectal metastases treated with SABR. The results support the use of SBRT in lung oligometastatic colorectal cancer patients as it might delay the transition to PMD or offer relatively long disease-free period in selected cases. Several biological and clinical predictive factors were identified to assure the highest local control, on the basis of which a decisional algorithm will be derived.

Published
2021

9. Treatment volume, dose prescription and delivery techniques for dose-intensification in Rectal Cancer: A national survey

Author

Monica Di Tommaso, Paola Franzone, Mattia Falchetto Osti, Vania Marchetti, Alessio G. Morganti, Giuditta Chiloiro, N. Simoni, R.M. Niespolo, Consuelo Rosa, Luciana Caravatta, Maria Antonietta Gambacorta, Cristina Piva, Maria Assunta Deidda, Vincenzo Picardi, L. Gasparini, Vittorio Donato, Domenico Genovesi, Fernando Munoz, Cesare Guida, S. Montrone, Corrado Spatola, Giovanna Mantello, Francesca Facchin, Pierfrancesco Franco, L. Ziccarelli, Marco Lupattelli, Caterina Boso, Giovanni Ivaldi, Caravatta L., Lupattelli M., Mantello G., Gambacorta M.A., Chiloiro G., Di Tommaso M., Rosa C., Gasparini L., Morganti A.G., Picardi V., Niespolo R.M., Osti M.F., Montrone S., Simoni N., Boso C., Facchin F., Deidda M.A., Piva C., Guida C., Ziccarelli L., Munoz F., Ivaldi G.B., Marchetti V., Franzone P., Spatola C., Franco P., Donato V., and Genovesi D.

Subjects
Male, Cancer Research, Colorectal cancer, Intensity modulated radiotherapy, medicine.medical_treatment, Radiotherapy Planning, Practice Patterns, Computer-Assisted, Surveys and Questionnaires, Positron Emission Tomography Computed Tomography, Intensity-Modulated, Simultaneous integrated boost, Surveys and Questionnaire, Rectal cancer, Practice Patterns, Physicians', Settore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA, medicine.diagnostic_test, Radiotherapy Dosage, General Medicine, Magnetic Resonance Imaging, Gross tumor volume, Tumor Burden, Oncology, Image-Guided, Italy, Lymphatic Metastasis, Female, Survival Analysi, Human, medicine, Humans, Dose intensification, Neoplasm Staging, Physicians', Radiotherapy, Rectal Neoplasm, business.industry, Rectal Neoplasms, Radiotherapy Planning, Computer-Assisted, Magnetic resonance imaging, Lymphatic Metastasi, medicine.disease, Survival Analysis, Dose prescription, Radiation therapy, Positron-Emission Tomography, Radiotherapy, Intensity-Modulated, Nuclear medicine, business, Volume (compression), Radiotherapy, Image-Guided
Abstract

Background/aim The aim of the study was to investigate boost volume definition, doses, and delivery techniques for rectal cancer dose intensification. Patients and methods An online survey was made on 25 items (characteristics, simulation, imaging, volumes, doses, planning and treatment). Results Thirty-eight radiation oncologists joined the study. Twenty-one delivered long-course radiotherapy with dose intensification. Boost volume was delineated on diagnostic magnetic resonance imaging (MRI) in 18 centres (85.7%), and computed tomography (CT) and/or positron emission tomography-CT in 9 (42.8%); 16 centres (76.2%) performed co-registration with CT-simulation. Boost dose was delivered on gross tumor volume in 10 centres (47.6%) and on clinical target volume in 11 (52.4%). The most common total dose was 54-55 Gy (71.4%), with moderate hypofractionation (85.7%). Intensity-modulated radiotherapy (IMRT) was used in all centres, with simultaneous integrated boost in 17 (80.8%) and image-guidance in 18 (85.7%). Conclusion A high quality of treatment using dose escalation can be inferred by widespread multidisciplinary discussion, MRI-based treatment volume delineation, and radiation delivery relying on IMRT with accurate image-guided radiation therapy protocols.

Published
2021

10. OC-0602 A pREDictive model of polymetastatic disease on oligometastatic colorectal cancer: the RED LaIT-SABR

Author

L. Nicosia, D. Franceschini, F. Perrone Congedi, F. Casamassima, M.A. Gerardi, M. Rigo, R. Mazzola, M. Perna, V. Scotti, A. Fodor, A. Iurato, F. Pasqualetti, G. Gadducci, S. Chiesa, R.M. Niespolo, A. Bruni, G. Alicino, L. Frassinelli, P. Borghetti, A. Di Marzo, A. Ravasio, B. De Bari, M. Sepulcri, D. Aiello, G. Mortellaro, C. Sangalli, M. Franceschini, G. Montesi, F.M. Aquilanti, G. Lunardi, R. Valdagni, I. Fazio, L. Corti, V. Vavassori, E. Maranzano, S.M. Magrini, S. Arcangeli, V. Valentini, F. Paiar, S. Ramella, N.G. Di Muzio, L. Livi, B.A. Jereczek- Fossa, M.F. Osti, M. Scorsetti, and F. Alongi

Subjects
Oncology, Radiology, Nuclear Medicine and imaging, Hematology
Published
2022

12. Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter case‐control study (PAULA‐1)

Author

Alessandra Arcelli, Milly Buwenge, Gabriella Macchia, Federica Bertini, Alessandra Guido, Francesco Deodato, Savino Cilla, Valerio Scotti, Maria Elena Rosetto, Igor Djan, Salvatore Parisi, Gian Carlo Mattiucci, Francesco Cellini, Michele Fiore, Pierluigi Bonomo, Liliana Belgioia, Rita Marina Niespolo, Pietro Gabriele, Mariacristina Di Marco, Nicola Simoni, Renzo Mazzarotto, Alessio Giuseppe Morganti, the AIRO (Italian Association of Radiation Oncology and Clinical Oncology) Gastrointestinal Study Group, and Alessandra Arcelli, Milly Buwenge, Gabriella Macchia, Federica Bertini, Alessandra Guido, Francesco Deodato, Savino Cilla, Valerio Scotti, Maria Elena Rosetto, Igor Djan, Salvatore Parisi, Gian Carlo Mattiucci, Francesco Cellini, Michele Fiore, Pierluigi Bonomo, Liliana Belgioia, Rita Marina Niespolo, Pietro Gabriele, Mariacristina Di Marco, Nicola Simoni, Renzo Mazzarotto, Alessio Giuseppe Morganti

Subjects
Male, 0301 basic medicine, Cancer Research, Time Factors, medicine.medical_treatment, pancreatic cancer, radiation therapy, conventionally fractionated radiotherapy, stereotactic body radiotherapy, 0302 clinical medicine, Risk Factors, 80 and over, Medicine, Neoplasm Metastasis, Stage (cooking), Dose Fractionation, Original Research, Settore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA, conventionally fractionated radiotherapy, pancreatic cancer, radiation therapy, stereotactic body radiotherapy, Aged, 80 and over, Radiation, Chemoradiotherapy, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Progression-Free Survival, Italy, Oncology, 030220 oncology & carcinogenesis, Toxicity, Cohort, Female, Adult, Radiosurgery, lcsh:RC254-282, 03 medical and health sciences, Pancreatic cancer, Humans, Radiology, Nuclear Medicine and imaging, Survival analysis, Aged, Retrospective Studies, Chemotherapy, business.industry, Case-control study, Clinical Cancer Research, medicine.disease, Pancreatic Neoplasms, Radiation therapy, 030104 developmental biology, Dose Fractionation, Radiation, business, Nuclear medicine
Abstract

Conventionally fractionated chemoradiation (CRT) or chemotherapy (CHT) are considered as standard options in locally advanced pancreatic cancer (LAPC) while stereotactic body radiotherapy (SBRT) is an emerging treatment in this setting. The aim of this study was to compare two cohorts of LAPC patients treated with SBRT ± CHT vs CRT ± CHT in terms of local control (LC), distant metastases‐free survival (DMFS), progression‐free survival (PFS), overall survival (OS), and toxicity. Eighty patients were included. Patients in the two cohorts were matched according to: age ≤/>65 years, tumor diameter (two cut‐offs, An equivalence of stereotactic body radiotherapy (SBRT) and chemoradiation (CRT) has been only suggested in some retrospective studies in pancreatic cancer (PC). This is the first matched case‐control study comparing SBRT and CRT in PC considering several endpoints. An equivalence in terms of overall survival, disease free survival, and metastasis free survival among the two treatments and an advantage of SBRT in terms of local control were recorded. Therefore, SBRT is almost comparable to standard CRT.

Published
2020

13. Radiotherapy with Intensity-Modulated (IMRT) Techniques in the Treatment of Anal Carcinoma (RAINSTORM): A Multicenter Study on Behalf of AIRO (Italian Association of Radiotherapy and Clinical Oncology) Gastrointestinal Study Group

Author

Gabriella Macchia, Francesca Valvo, L. Gasparini, Alessandra Galardi, Maria Rosaria Lucido, Luciana Caravatta, Vittorio Donato, Giovani Battista Ivaldi, Marianna Alessandra Gerardi, Badr El Khouzai, Stefano Vagge, Marta Di Nicola, Alessandra Guido, R.M. Niespolo, Marco Lupattelli, Fernando Munoz, Giovanna Mantello, E. Palazzari, Annamaria Porreca, Patrizia Pittoni, M.E. Rosetto, Gianpiero Catalano, Maria Antonietta Gambacorta, Alessandra Gonnelli, Francesca De Felice, Oreste Durante, Najla Slim, Stefania Manfrida, Domenico Genovesi, Maria Falchetto Osti, Consuelo Rosa, Pierfrancesco Franco, and Marco Krengli

Subjects
0301 basic medicine, Cancer Research, medicine.medical_specialty, Anal Carcinoma, medicine.medical_treatment, anal carcinoma, lcsh:RC254-282, Gastroenterology, Article, 03 medical and health sciences, Anal carcinoma, Concomitant radio-chemotherapy, Intensity-modulated radiotherapy, Simultaneous integrated boost, 0302 clinical medicine, concomitant radio-chemotherapy, Internal medicine, medicine, Anal cancer, Lymph node, Settore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA, business.industry, Retrospective cohort study, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, intensity-modulated radiotherapy, Intensity (physics), Radiation therapy, 030104 developmental biology, medicine.anatomical_structure, Oncology, Multicenter study, 030220 oncology & carcinogenesis, simultaneous integrated boost, Cohort, business
Abstract

Simple Summary Concurrent chemo-radiotherapy is the standard treatment in anal cancer. Intensity-modulated radiotherapy (IMRT) was proved to reduce severe, acute and late toxicities. Moreover, IMRT techniques allow for the planning and delivery of a simultaneous integrated boost (SIB), with a differential dose per fraction given to selected sub-regions during the same treatment session. This boost modality provides the chance to employ a dose-painted approach with a reduction in overall treatment time that could result in a potential clinical advantage. Since a large variability in dose prescription to the primary tumor and elective or involved lymph nodes can be found in available guidelines and clinical practice, a multicenter analysis was conducted to evaluate the pattern of care and the impact of radiotherapy parameters on clinical outcomes for anal cancer patients treated with IMRT techniques within a national cohort. Abstract A multi-institutional retrospective study was conducted to evaluate the pattern of care and clinical outcomes of anal cancer patients treated with intensity-modulated radiotherapy (IMRT) techniques. In a cohort of 987 patients, the clinical complete response (CR) rate (beyond 6 months) was 90.6%. The 3-year local control (LC) rate was 85.8% (95% CI: 84.4–87.2), and the 3-year colostomy-free survival (CFS) rate was 77.9% (95% CI: 76.1–79.8). Three-year progression-free survival (PFS) and overall survival (OS) rates were 80.2% and 88.1% (95% CI: 78.8–89.4) (95% CI: 78.5–81.9), respectively. Histological grade 3 and nodal involvement were associated with lower CR (p = 0.030 and p = 0.004, respectively). A statistically significant association was found between advanced stage and nodal involvement, and LC, CFS, PFS, OS and event-free survival (EFS). Overall treatment time (OTT) ≥45 days showed a trend for a lower PFS (p = 0.050) and was significantly associated with lower EFS (p = 0.030) and histological grade 3 with a lower LC (p = 0.025). No statistically significant association was found between total dose, dose/fraction and/or boost modality and clinical outcomes. This analysis reports excellent clinical results and a mild toxicity profile, confirming IMRT techniques as standard of care for the curative treatment of anal cancer patients. Lymph node involvement and histological grade have been confirmed as the most important negative prognostic factors.

Published
2021

14. PD-0918 Stereobody radiotherapy vs chemoradiation in elderly with locally advanced pancreatic cancer

Author

M. Buwenge, Renzo Mazzarotto, Francesco Cellini, G. Tolento, Alessandra Arcelli, M.E. Rosetto, Silvia Cammelli, Alessio G. Morganti, R.M. Niespolo, Alessandra Guido, Vieri Scotti, Pietro Bonomo, F. Bertini, Gabriella Mattiucci, M. Di Marco, I. Djan, Liliana Belgioia, N. Simoni, Gabriella Macchia, Michele Fiore, Pietro Gabriele, Salvatore Parisi, Savino Cilla, and F. Deodato

Subjects
Oncology, Radiation therapy, medicine.medical_specialty, business.industry, Internal medicine, medicine.medical_treatment, Medicine, Radiology, Nuclear Medicine and imaging, Hematology, business, Locally advanced pancreatic cancer
Published
2021

15. PH-0112 Multicenter large retrospectIve database on SBRT for colorectal lung metastases: the LaIT-SABR study

Author

Riccardo Valdagni, L. Vavassori, Michele Rigo, Marianna Alessandra Gerardi, B. De Bari, N. Di Muzio, Barbara Alicja Jereczek-Fossa, Vieri Scotti, Frank Lohr, M. Perna, Filippo Alongi, Luigi Corti, I. Fazio, R.M. Niespolo, G. Mortellaro, F.M. Aquilanti, Andrei Fodor, Paolo Borghetti, M.F. Osti, Luca Nicosia, A. Ravasio, Davide Franceschini, L. Frassinelli, A. Di Marzo, G. Gadducci, A. Iurato, Fabiola Paiar, D. Aiello, Alessio Bruni, F. Casamassima, Sara Ramella, Silvia Chiesa, Rosario Mazzola, F. Perrone Congedi, Stefano Arcangeli, Stefano Maria Magrini, M. Franceschini, Lorenzo Livi, M. Sepulcri, Francesco Pasqualetti, Claudia Sangalli, Marta Scorsetti, Ernesto Maranzano, Giampaolo Montesi, and V. Valentini

Subjects
medicine.medical_specialty, Lung, medicine.anatomical_structure, Oncology, business.industry, Medicine, Radiology, Nuclear Medicine and imaging, Hematology, Radiology, business, SABR volatility model, Retrospective database
Published
2021

16. OC-0620 A multicenter study on Intensity Modulated Radiotherapy techniques for anal carcinoma (RAINSTORM)

Author

Stefano Vagge, Mattia Falchetto Osti, Marco Lupattelli, Alessandra Galardi, F. Pierfrancesco, E. Palazzari, Giovanni Ivaldi, Marianna Alessandra Gerardi, Giovanna Mantello, Gabriella Macchia, P. Pittoni, G. Lucrezia, F. De Felice, Francesca Valvo, M. Di Nicola, Gianpiero Catalano, M.A. Gambacorta, R.M. Niespolo, Alessandra Guido, Luciana Caravatta, Violante Di Donato, Najla Slim, Domenico Genovesi, Marco Krengli, and Consuelo Rosa

Subjects
medicine.medical_specialty, Oncology, Multicenter study, business.industry, Anal Carcinoma, Medicine, Radiology, Nuclear Medicine and imaging, Hematology, Intensity modulated radiotherapy, Radiology, business
Published
2021

18. Genomic and Functional Regulation of TRIB1 Contributes to Prostate Cancer Pathogenesis

Author

Amaia Zabala-Letona, Laura Camacho, Maider Bizkarguenaga, Endre Kiss-Toth, Arkaitz Carracedo, Ianire Astobiza, Isabel Mendizabal, Parastoo Shahrouzi, Ruben Caloto, Chiara Niespolo, Guillermo Velasco, Alice Macchia, Edurne Berra, Ana R. Cortazar, Juana M. Flores, Xosé R. Bustelo, Leire Arreal, María L. Martínez-Chantar, Verónica Torrano, Amaia Ercilla, European Commission, Fundación Vasca de Innovación e Investigación Sanitarias, Asociación Española Contra el Cáncer, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Ministerio de Economía y Competitividad (España), Eusko Jaurlaritza, Fundación BBVA, Fundación 'la Caixa', European Research Council, Instituto de Salud Carlos III, and Centro de Investigación Biomédica en Red Cáncer (España)

Subjects
0301 basic medicine, Cancer Research, Disease, Biology, Mouse models, lcsh:RC254-282, Article, Oncología, Pathogenesis, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Transcription (biology), medicine, mouse models, Transcription factor, Gene, cMYC, Oncogene, TRIB1, Amplicon, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, prostate cancer, Genética, 3. Good health, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Cancer research
Abstract

© 2020 by the authors., Prostate cancer is the most frequent malignancy in European men and the second worldwide. One of the major oncogenic events in this disease includes amplification of the transcription factor cMYC. Amplification of this oncogene in chromosome 8q24 occurs concomitantly with the copy number increase in a subset of neighboring genes and regulatory elements, but their contribution to disease pathogenesis is poorly understood. Here we show that TRIB1 is among the most robustly upregulated coding genes within the 8q24 amplicon in prostate cancer. Moreover, we demonstrate that TRIB1 amplification and overexpression are frequent in this tumor type. Importantly, we find that, parallel to its amplification, TRIB1 transcription is controlled by cMYC. Mouse modeling and functional analysis revealed that aberrant TRIB1 expression is causal to prostate cancer pathogenesis. In sum, we provide unprecedented evidence for the regulation and function of TRIB1 in prostate cancer., We are grateful to the Carracedo lab for valuable input, to Ana M. Aransay and F. Elortza for technical advice. P.S. was funded by the European Training Networks Project (H2020-MSCA-ITN-308 2016 721532). V.T. is funded by Fundación Vasca de Innovación e Investigación Sanitarias, BIOEF (BIO15/CA/052), the AECC J.P. Bizkaia, the Basque Department of Health (2016111109) and the MICINN RTI2018-097267-B-I00. A. Macchia was funded by a FPI predoctoral fellowship from MICINN (PRE2018-083607). EB is funded by the MICINN (BFU2016-76872-R (FEDER/EU), PID2019-108112RB-I00, Severo Ochoa Excellence Accreditation SEV-2016-0644 and Excellence Networks SAF2017-90794-REDT). The work of A. Carracedo is supported by the Basque Department of Industry, Tourism and Trade (Elkartek), the department of education (IKERTALDE IT1106-16) and health (RIS3), the BBVA foundation and the MICINN (SAF2016-79381-R (FEDER/EU; PID2019-108787RB-I00) Severo Ochoa Excellence Accreditation SEV-2016-0644 and Excellence Networks SAF2016-81975-REDT and RED2018-102769-T), European Training Networks Project (H2020-MSCA-ITN-308 2016 721532), the AECC (IDEAS175CARR, GCTRA18006CARR), La Caixa Foundation (ID 100010434), under the agreement LCF/PR/HR17/ and the European Research Council (Starting Grant 336343, Consolidator Grant 819242). CIBERONC was co-funded with FEDER funds and funded by ISCIII.

Published
2020

19. PO-1042: SBRT vs conventionally fractionated radiochemotherapy for pancreatic cancer: a case-control study

Author

I. Djan, Alessio G. Morganti, Francesco Deodato, G.C. Mattiucci, Renzo Mazzarotto, Alessandra Arcelli, F. Bertini, Almalina Bacigalupo, Pietro Gabriele, Vieri Scotti, Salvatore Parisi, Savino Cilla, R.M. Niespolo, Alessandra Guido, N. Simoni, Gabriella Macchia, Michele Fiore, M.E. Rosetto, Silvia Cammelli, and Pierluigi Bonomo

Subjects
Oncology, medicine.medical_specialty, business.industry, Internal medicine, Pancreatic cancer, medicine, Case-control study, Radiology, Nuclear Medicine and imaging, Hematology, business, medicine.disease
Published
2020

21. Time to surgery and pathologic complete response after neoadjuvant chemoradiation in rectal cancer: A population study on 2094 patients

Author

Fabio Matrone, Maika di Benedetto, Giampaolo Montesi, Gabriella Macchia, Giuditta Chiloiro, Liliana Belgioia, E. Palazzari, R.M. Niespolo, Francesco Romeo Filippone, L. Giaccherini, M.E. Rosetto, Aldo Sainato, Salvatore Parisi, Luciana Caravatta, Antonino De Paoli, Mattia Falchetto Osti, Piera Sciacero, A. Fontana, Vincenzo Valentini, A. Caroli, Carlo Capirci, Caterina Boso, Lucia Turri, Alessio G. Morganti, Maria Antonietta Gambacorta, S. Montrone, Almalina Bacigalupo, Domenico Genovesi, Vincenzo Picardi, Alessandra Galardi, Carlotta Masciocchi, Marco Lupattelli, Giovanna Mantello, Macchia, Gabriella, Gambacorta, Maria Antonietta, Masciocchi, Carlotta, Chiloiro, Giuditta, Mantello, Giovanna, di Benedetto, Maika, Lupattelli, Marco, Palazzari, Elisa, Belgioia, Liliana, Bacigalupo, Almalina, Sainato, Aldo, Montrone, Sabrina, Turri, Lucia, Caroli, Angela, De Paoli, Antonino, Matrone, Fabio, Capirci, Carlo, Montesi, Giampaolo, Niespolo, Rita Marina, Osti, Mattia Falchetto, Caravatta, Luciana, Galardi, Alessandra, Genovesi, Domenico, Rosetto, Maria Elena, Boso, Caterina, Sciacero, Piera, Giaccherini, Lucia, Parisi, Salvatore, Fontana, Antonella, Filippone, Francesco Romeo, Picardi, Vincenzo, Morganti, Alessio Giuseppe, and Valentini, Vincenzo

Subjects
medicine.medical_specialty, Colorectal cancer, medicine.medical_treatment, Urology, R895-920, 030230 surgery, Article, 03 medical and health sciences, Medical physics. Medical radiology. Nuclear medicine, 0302 clinical medicine, Chemoradiation, Rectal cancer, Surgery, TME, Time interval, Rectal Adenocarcinoma, Medicine, Radiology, Nuclear Medicine and imaging, Stage (cooking), RC254-282, Settore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA, Chemotherapy, business.industry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Retrospective cohort study, medicine.disease, Total mesorectal excision, Radiation therapy, Oncology, 030220 oncology & carcinogenesis, Population study, business
Abstract

Highlights • A large population based analysis to evaluate pathologic response according to time of surgery. • LARC patients were treated with modern techniques of radiotherapy and surgery. • The rate of pCR increased according to time interval from 12.6% to 31.1%. • The pCR increasing was 1.5% (about 0.2%/die) per each week of waiting. • Lengthening the interval (>13 weeks) significantly improved the pathological response., Background To retrospectively evaluate the difference in terms of pathologic complete response (pCR) according to time elapsed between chemoradiation (CRT) and total mesorectal excision (TME) on a large unselected real-life dataset of locally advanced rectal cancer (LARC) patients. Methods A multicentre retrospective cohort study of LARC patients from 21 Italian Radiotherapy Institutions was performed. Patients were stratified into 3 different time intervals from CRT. The 1st group included 300 patients who underwent TME within 6 weeks, the 2nd 1598 patients (TME within 7–12 weeks) and the 3rd 196 patients (TME within 13 or more weeks after CRT), respectively. Results Data on 2094 LARC patients treated between 1997 and 2016 were considered suitable for analysis. Overall, 578 patients had stage II while 1516 had stage III histological proven invasive rectal adenocarcinoma. A CRT schedule of one agent (N = 1585) or 2-drugs (N = 509) was administered. Overall, pCR was 22.3% (N = 468 patients). The proportion of patients achieving pCR with respect to time interval was, as follows: 12.6% (1st group), 23% (2nd group) and 31.1% (3rd group) (p 5040 cGy (p = 0.002) and longer interval (p 13 weeks) from CRT to surgery improves the pathological response (pCR and pathologic partial response; pPR) in comparison to historic data. Furthermore, radiotherapy dose >5040 cGy and two drugs chemotherapy correlated with pPR rate.

Published
2017

22. EP-1423 SBRT in locally advanced pancreatic cancer: a real-life study (PAULA-1)

Author

Pietro Gabriele, Renzo Mazzarotto, Pierluigi Bonomo, F. Dalla Torre, Salvatore Parisi, Savino Cilla, N. Simoni, M.E. Rosetto, R.M. Niespolo, Vieri Scotti, Alessandra Guido, Alessio G. Morganti, Alessandra Arcelli, G.C. Mattiucci, Gabriella Macchia, Michele Fiore, Almalina Bacigalupo, I. Djan, and D. Francesco

Subjects
Oncology, medicine.medical_specialty, business.industry, Internal medicine, Medicine, Radiology, Nuclear Medicine and imaging, Hematology, business, Life study, Locally advanced pancreatic cancer
Published
2019

23. EP-1424 SBRT vs chemoradiation: a case-control study (PAULA-2)

Author

Vieri Scotti, Alessandra Arcelli, M.E. Rosetto, Pietro Gabriele, F. Dalla Torre, Alessio G. Morganti, Salvatore Parisi, F. Deodato, Savino Cilla, R.M. Niespolo, Alessandra Guido, Pierluigi Bonomo, Gabriella Macchia, Michele Fiore, I. Djan, N. Simoni, Almalina Bacigalupo, F. Bertini, Renzo Mazzarotto, and G.C. Mattiucci

Subjects
medicine.medical_specialty, Oncology, business.industry, Case-control study, Medicine, Radiology, Nuclear Medicine and imaging, Hematology, Radiology, business
Published
2019

24. PO-0809 Gross Tumor Volume delineation in pancreatic cancer using MRI: final results of a multicenter study

Author

Alessio G. Morganti, Francesco Cellini, Roberta Cianci, Aldo Sainato, Vincenzo Fusco, F. Navarria, Francesco Dionisi, Gabriella Macchia, A. De Paoli, Vincenzo Picardi, R.M. Niespolo, M.E. Rosetto, M. Di Nicola, Giovanna Mantello, Consuelo Rosa, Domenico Genovesi, Claudio Vecchi, V. Valentini, G.C. Mattiucci, A. Delli Pizzi, Marco Lupattelli, Raffaella Basilico, Alessandra Guido, Luciana Caravatta, and N. Simoni

Subjects
Oncology, Multicenter study, business.industry, Pancreatic cancer, medicine, Radiology, Nuclear Medicine and imaging, Hematology, medicine.disease, business, Nuclear medicine, Gross tumor volume
Published
2019

25. PO-0775: MRI for GTV delineation in pancreatic cancer: preliminary results of a multi-institutional study

Author

Domenico Genovesi, Vincenzo Fusco, Luciana Caravatta, A. De Paoli, Giovanna Mantello, Marco Lupattelli, N. Simoni, Raffaella Basilico, R.M. Niespolo, Vincenzo Picardi, Alessio G. Morganti, Consuelo Rosa, Francesco Dionisi, Gabriella Macchia, Giovanni Boz, G.C. Mattiucci, Aldo Sainato, M.E. Rosetto, Cesare Guida, and Francesco Cellini

Subjects
medicine.medical_specialty, Oncology, business.industry, Pancreatic cancer, medicine, Radiology, Nuclear Medicine and imaging, Hematology, Radiology, medicine.disease, business
Published
2018

26. Adjuvant chemoradiotherapy in gastric cancer: A pooled analysis of the AIRO Gastrointestinal Group experience

Author

Antonietta Augurio, Vincenzo Fusco, Antonella Melano, Piera Sciacero, Francesca Corazzi, Gian Carlo Mattiucci, Chiara Valentini, Vincenzo Picardi, Tiziana Iannone, Marco Luppattelli, Paola Murino, Stefania Manfrida, Alessio G. Morganti, Domenico Genovesi, Mattia Falchetto Osti, Antonino De Paoli, Maria Grazia Mangiacotti, Vincenzo Valentini, Giuseppe Pani, Giuseppe D'Agostino, Alessandra Huscher, Carlo Capirci, M.E. Rosetto, R.M. Niespolo, Mattiucci, Gian Carlo, Valentini, Chiara, D'Agostino, Giuseppe Roberto, Augurio, Antonietta, Capirci, Carlo, De Paoli, Antonino, Genovesi, Domenico, Huscher, Alessandra, Iannone, Tiziana, Pani, Giuseppe, Rosetto, Maria Elena, Sciacero, Piera, Manfrida, Stefania, Corazzi, Francesca, Fusco, Vincenzo, Luppattelli, Marco, Mangiacotti, Maria Grazia, Melano, Antonella, Murino, Paola, Niespolo, Rita, Osti, Mattia Falchetto, Picardi, Vincenzo, Morganti, Alessio Giuseppe, and Valentini, Vincenzo

Subjects
Male, Cancer Research, Multivariate analysis, Neoplasm, Residual, Survival, medicine.medical_treatment, Gastroenterology, Retrospective Studie, Antineoplastic Combined Chemotherapy Protocols, Adjuvant, Settore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA, Medicine (all), Radiotherapy Dosage, General Medicine, Chemoradiotherapy, Middle Aged, Treatment Outcome, Italy, Oncology, Residual, Toxicity, Female, Human, Adult, medicine.medical_specialty, adjuvant chemoradiotherapy, gastric cancer, survival, toxicity, treatment compliance, adult, aged, antineoplastic combined chemotherapy protocols, disease-free survival, drug administration schedule, female, humans, italy, male, middle aged, neoplasm grading, neoplasm staging, neoplasm, residual, radiotherapy dosage, retrospective studies, stomach neoplasms, treatment outcome, chemoradiotherapy, adjuvant, gastrectomy, medicine (all), oncology, cancer research, Disease-Free Survival, Drug Administration Schedule, Stomach Neoplasms, Adjuvant chemoradiotherapy, Stomach Neoplasm, Gastrectomy, Internal medicine, medicine, Humans, Retrospective Studies, Aged, Neoplasm Staging, Chemotherapy, Antineoplastic Combined Chemotherapy Protocol, business.industry, Cancer, Retrospective cohort study, Chemoradiotherapy, Adjuvant, medicine.disease, Surgery, Radiation therapy, Neoplasm, Treatment compliance, Neoplasm Grading, business, Gastric cancer
Abstract

Background Given the poor compliance with adjuvant chemoradiotherapy (CRT) in gastric cancer reported in previous studies, a survey was conducted among 18 Italian institutions within the AIRO Gastrointestinal Group to investigate current treatment modalities, toxicities, and compliance with adjuvant CRT. Patients and Methods Data from 348 patients operated on for gastric cancer were collected retrospectively from September 2000 to June 2008 and analyzed. The adjuvant treatments included CRT according to center guidelines. In multivariate analysis, acute hematological, gastrointestinal, and renal toxicity (according to the RTOG Acute Radiation Morbidity Scoring Criteria) and compliance with treatment were studied, as well as risk factors for local control, metastasis-free survival, disease-free survival, and overall survival. Results Compliance with treatment was excellent: 95.7% of patients completed CRT. During CRT, acute G3-G4 hematological toxicity was 3.7% and acute G3-G4 gastrointestinal toxicity 4%. 78.4% of patients completed chemotherapy (CT), either before or after CRT. During CT acute G3-G4 hematological toxicity was 5.4% and acute G3-G4 gastrointestinal toxicity 6%. Overall, 74.1% of patients completed the prescribed treatment (CRT and CT). Doses greater than 4500 cGy did not compensate for more aggressive disease. The 5-year overall survival was 51%. Conclusions The adjuvant treatment of gastric cancer within the AIRO group was diverse, but radiotherapy treatment was homogeneous (in terms of technique) and well tolerated. Toxicity was low and compliance with treatment was good during CRT; these results may be due to the radiotherapy technique applied. This survey could be used as a benchmark for further studies.

Published
2015

27. PO-0680: SBRT for locally advanced pancreatic cancer (LAPC): a retrospective multi-institutional experience

Author

Gabriella Macchia, Vieri Scotti, Michele Fiore, Alessandra Guido, I. Djan, Alessandra Arcelli, Pierluigi Bonomo, Francesco Deodato, Almalina Bacigalupo, G.C. Mattiucci, Alessio G. Morganti, M.E. Rosetto, R.M. Niespolo, Pietro Gabriele, F. Dalla Torre, Salvatore Parisi, Savino Cilla, F. Bertini, Lorenzo Fuccio, and V. Valentini

Subjects
Oncology, medicine.medical_specialty, business.industry, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Hematology, business, Locally advanced pancreatic cancer
Published
2017

28. PV-0326: Time to surgery and pCR after neoadjuvant CRT in rectal cancer: a population study on 2113 patients

Author

L. Giaccherini, Gabriella Macchia, M.A. Gambacorta, Alessandra Galardi, A. De Paoli, Luciana Caravatta, Caterina Boso, Giampaolo Montesi, Mattia Falchetto Osti, Carlotta Masciocchi, Marco Lupattelli, Liliana Belgioia, M.E. Rosetto, F. Perrotti, Salvatore Parisi, Lucia Turri, R.M. Niespolo, Francesco Romeo Filippone, Giovanna Mantello, Piera Sciacero, V. Valentini, Giuditta Chiloiro, Alessio G. Morganti, Aldo Sainato, and A. Fontana

Subjects
medicine.medical_specialty, Oncology, Colorectal cancer, business.industry, Time to surgery, medicine, Population study, Radiology, Nuclear Medicine and imaging, Hematology, medicine.disease, business, Surgery
Published
2017

29. PO-0681: SBRT VS standard chemoradiation in locally advanced pancreatic cancer (LAPC): a case-control study

Author

R.M. Niespolo, Almalina Bacigalupo, Alessandra Guido, Pierluigi Bonomo, Vieri Scotti, F. Bertini, Lorenzo Fuccio, I. Djan, Pietro Gabriele, Alessio G. Morganti, F. Dalla Torre, Salvatore Parisi, Savino Cilla, Gabriella Macchia, E.M. Rosetto, Alessandra Arcelli, Michele Fiore, Francesco Deodato, G.C. Mattiucci, and V. Valentini

Subjects
Oncology, medicine.medical_specialty, business.industry, Internal medicine, Case-control study, medicine, Radiology, Nuclear Medicine and imaging, Hematology, business, Locally advanced pancreatic cancer
Published
2017

30. O-019 Distant-relapse analysis of STAR-01, a randomized phase III trial comparing preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer

Author

Michela Frisinghelli, G. Aprile, Cristiana Corsi, Stefano Cordio, Gabriele Luppi, Cristina Granetto, A.R. Marsella, Maria Emanuela Negru, A. Sartore Bianchi, Andrea Bonetti, Carlo Aschele, Vittorina Zagonel, Angiolo Tagliagambe, Gerardo Rosati, Luigi Boni, Maria Chiara Tronconi, Carmine Pinto, S. Lonardi, Anna Maria Bochicchio, R. Niespolo, Luca Cionini, and Paola Rosetti

Subjects
Oncology, Preoperative chemoradiotherapy, medicine.medical_specialty, business.industry, Colorectal cancer, Locally advanced, Hematology, medicine.disease, Preoperative care, Oxaliplatin, Internal medicine, Rectal carcinoma, medicine, Radiology, business, medicine.drug
Published
2016

31. Analysis of early distant metastases of STAR-01: A randomized phase III trial comparing preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer

Author

Carmine Pinto, Michela Frisinghelli, Francesca Bergamo, Cristina Granetto, Carlo Aschele, Katia Bencardino, Francesca Di Fabio, Luca Cionini, Rita Niespolo, Paola Rosetti, Germana Chiaulon, Angiolo Tagliagambe, Luca Boni, Maria Chiara Tronconi, Stefano Cordio, Gabriele Luppi, Sara Lonardi, Gerardo Rosati, Maria Emanuela Negru, and Andrea Bonetti

Subjects
Cancer Research, medicine.medical_specialty, Preoperative chemoradiotherapy, Colorectal cancer, business.industry, Locally advanced, medicine.disease, Total mesorectal excision, Oxaliplatin, Oncology, medicine, sense organs, Radiology, business, medicine.drug
Abstract

e15149Background: Despite standard preoperative pelvic chemoradiation (CRT) and optimal surgery with total mesorectal excision (TME) leading to local recurrence rates below 5% in locally advanced r...

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results